Related Experiment Video
Updated: Jul 11, 2025

A Simple Pit Assay Protocol to Visualize and Quantify Osteoclastic Resorption In Vitro
Published on: June 16, 2022
The JNK signaling pathway against titanium-particle-induced osteoclastogenesis and bone resorption in vivo
1School of Clinical Medicine, Guangxi Medical University, Nanning, China. chendesheng@nxmu.edu.cn.
Objective:
The c-Jun N-terminal kinases (JNK) signaling pathway may be involved in the regulation of osteoclast development. The purpose of this investigation was to investigate whether SB600125, a JNK inhibitor, could attenuate titanium-particle-induced inflammatory osteolysis in vivo.
Materials And Methods:
A total of 45 mice were randomly divided into a Sham group, a Titanium group, and a Titanium + JNK inhibitor group, 15 mice per group. After establishing an air pouch bone graft model, we injected phosphate-buffered saline (PBS), titanium particles, or titanium particles + JNK inhibitor into the air pouch of the three groups. The pouch membranes containing bone implants were taken for morphological and molecular analysis 14 days after the mice were sacrificed.
Results:
General morphological structure observation results, Hematoxylin and Eosin (H&E)-Stained Sections, anti-tartaric acid phosphatase (TRAP) staining, and the transmission electron microscope showed that SB600125, by inhibiting the expression of JNK, attenuated titanium particle-induced inflammatory osteolysis (p<0.05). Immunohistochemical appearance results and reverse transcription-polymerase chain reaction (RT-PCR) results showed SB600125 reduced expression of IL-6, and TNF-α in osteolytic sites stimulated with wear debris (p<0.05). The Western blot results showed the expression of the p-JNK protein in the titanium particle + SB600125 group was significantly reduced compared to the titanium particle stimulation group (p<0.05).
Conclusions:
Interfering with the JNK signaling pathway may be beneficial in reducing osteolysis, providing a therapeutic target for preventing and treating aseptic loosening caused by debris-induced inflammatory osteolysis.
Insights
SB600125, a JNK inhibitor, reduced titanium particle-induced osteolysis by decreasing inflammatory markers. This suggests targeting the JNK pathway may treat aseptic loosening from wear debris.
Area of Science:
- Biomedical Engineering
- Immunology
- Orthopedics
Background:
- The c-Jun N-terminal kinases (JNK) signaling pathway is implicated in osteoclast development.
- Titanium particle-induced osteolysis is a significant concern in orthopedic implant loosening.
Purpose of the Study:
- To investigate the efficacy of SB600125, a JNK inhibitor, in attenuating titanium particle-induced inflammatory osteolysis in vivo.
Main Methods:
- An air pouch bone graft model was established in mice.
- Mice were divided into Sham, Titanium, and Titanium + JNK inhibitor groups.
- Morphological and molecular analyses were performed on pouch membranes.
Main Results:
- SB600125 significantly attenuated titanium particle-induced osteolysis by inhibiting JNK expression (p<0.05).
- SB600125 reduced IL-6 and TNF-α expression in osteolytic sites (p<0.05).
- Western blot confirmed reduced p-JNK protein expression in the SB600125-treated group (p<0.05).
Conclusions:
- Inhibiting the JNK signaling pathway is beneficial in reducing osteolysis.
- Targeting the JNK pathway offers a potential therapeutic strategy for aseptic loosening caused by debris-induced inflammatory osteolysis.
Related Concept Videos
Osteoclasts in Bone Remodeling
The JAK-STAT Signaling Pathway
TGF - β Signaling Pathway
Bone Remodeling
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...

